Crown Equity Holdings CRWE Network Reaches 450 Community Websites in U.S and 10 in Canada

 

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

The company is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

The CRWE Network’s business model is based on selling advertising to local businesses.

Crown Equity Holdings has recently added to its network the communities of Zephyr Cove (www.zephyrcove.crwe-pr.com), located in Douglas County, Nevada and Kelowna (www.kelownacanada.crwe-pr.com), a city located in the Okanagan Valley of British Columbia, Canada.

The CRWE Network has reached the 450th community website in the U.S., associated with 1934 ZIP Codes (includes coverage of the greater state of California, Northern and Southern Nevada and Wellington in Florida) and 10 provinces in Canada

http://pennyomega.com/img/crweapr17.jpg

The CRWE-PR’s mobile marketing platform includes a coupon page for added readership and businesses value. The network offers business owners the power of consumer targeting advertisement on a local and national scale through offerings and deals with their restaurant, auto repair, realtor, bar, movie theater, retail business, golf course, auto dealership and any other variety of businesses existing within a community.

The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (www.medicalmarijuana.crwe-pr.com). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

http://pennyomega.com/img/crwecharap.png

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer at www.crownequityholdings.com/disclaimer.html

Read our Disclaimer

 
Share/Bookmark
 



                

BioCryst Pharmaceuticals (BCRX) BCX4430, a Hope in the Battle with Ebola, Dejour Energy (DEJ) Black Gold Knocks at the Door

http://pennyomega.com/img/penny_omega.jpg

chartstockalert

Since its inception in 1969, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has spearheaded research to develop medical solutions—vaccines, drugs, diagnostics, and information—to protect the U.S.’ military service members from biological threats. Its specialized capabilities include Biosafety Level 3 and Level 4 laboratories, world-class expertise in the generation of biological aerosols for testing candidate vaccines and therapeutics, and fully accredited animal research facilities.

As the United States continues a new era of civilian biodefense research, it is also clear that USAMRIID plays a critical role in the status of the U.S.’ preparedness for biological terrorism and biological warfare. While USAMRIID’s primary mission is to protect the warfighter, its research benefits civilians as well.

http://pennyomega.com/img/bcrx.jpg BioCryst Pharmaceuticals, Inc. (BCRX)

Filoviruses, such as Ebola virus and Marburg virus, are extremely virulent. These pathogens are classified as Category A Bioterrorism Agents by the Centers for Disease Control and Prevention. Marburg virus is a member of the family Filoviridae, along with Ravn virus, Ebola virus, Sudan virus and Bundibugyo virus, all of which cause severe viral hemorrhagic fevers in humans.

Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans, characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids.

More than 120 people have died from the latest Ebola outbreak in West Africa. With no cure or vaccine, it is one of the most deadly of viruses, killing between 60% to 90% of those infected.

Health officials do not expect the virus to go global and stress that Ebola is not easy to catch, requiring direct contact with an infected victim’s bodily fluids.

BCRX recently reported the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases.

The Nature online publication, “Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430,” (http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13027.html) represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BCRX.

Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

http://pennyomega.com/img/bcrxapr15.png

BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians.

More about BioCryst Pharmaceuticals, Inc. (BCRX) at www.BioCryst.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 433th community website in the U.S., associated with 1894 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE Network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://crwe-pr.com/wp-content/uploads/2013/12/CRWE_Network.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/dej.jpg Dejour Energy Inc. (DEJ)

Keep a close eye on DEJ. The company reported that gross daily production at its Woodrush project in NE British Columbia is currently 540 boepd (380 net), an increase of 60% over average gross daily production during the fourth 2013 of 316 boepd (237 net).

Recently, DEJ closed the purchase of certain natural gas producing assets and related processing facilities adjacent to its Woodrush oilfield 120 km. north of Ft. St. John, B.C.

The assets acquired include a 54% working interest in a currently producing Halfway formation well and a 74% working interest in 3 shut-in Halfway natural gas wells. One of those wells has now been reactivated and is producing an additional ~1mmcf/d into DEJ’s sales line at Woodrush.

DEJ is analyzing the best procedure for reactivating the remaining wells. Proven Developed Producing reserve additions are now being calculated.

In 2013, DEJ generated $9.3 million in gross revenues, a 35% increase over 2012, and positive cash flow from operations of $521,000 compared with a cash deficiency from operations of $2.2 million in 2012.

http://pennyomega.com/img/dej_apr15.png

DEJ is an independent oil and natural gas exploration and production company operating projects in North America’s Piceance Basin (approximately 71,500 net acres) and Peace River Arch regions (approximately 17,000 net acres).

More about Dejour Energy Inc. (DEJ) at www.dejour.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

Read our Disclaimer

 
Share/Bookmark
 



                

Zebra Technologies (ZBRA) Numbers Signals, Lannett Company (LCI) FDA Green Light for Bioequivalent Diazepam Oral Solution

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/zbra.jpg Zebra Technologies Corp. (ZBRA)

ZBRA reported that it expects to report sales for the first quarter of 2014 in the range of $287,000,000 to $289,000,000, or 21% over the $236,937,000 in sales reported for the same period the prior year, while ZBRA‘s earnings are expected in a range of $0.79 to $0.82 per share, up approximately 74% from $0.46 per share for the first quarter of 2013.

ZBRA also announced that it will acquire Motorola’s Enterprise business for $3.45 billion in an all-cash transaction.

http://pennyomega.com/img/zbra_chart.png

ZBRA offers technologies that give a virtual voice to an organization’s assets, people and transactions, enabling organizations to unlock greater business value.

More about Zebra Technologies Corp. (ZBRA) at www.Zebra.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 431th community website in the U.S., associated with 1887 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE Network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://pennyomega.com/img/crweapr15.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/lci.jpg Lannett Company, Inc. (LCI)

LCI reported that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug.

Diazepam Oral Solution (Concentrate), 5 mg/mL, is therapeutically equivalent to the reference listed drug, Diazepam Intensol Oral Solution (Concentrate), 5 mg/mL, of Roxane Laboratories, Inc.

http://pennyomega.com/img/lciabr15.png

LCI develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

More about Lannett Company, Inc. (LCI) at www.lannett.com.

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

Read our Disclaimer

 
Share/Bookmark
 



                

Lexicon (LXRX) Top-line Results In Type 1 Diabetes Clinical Trial, Crown Equity Holdings Adds Medical Marijuana Site to Its CRWE Network, Bebe Stores (BEBE) Upgraded

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/lxrx.jpg Lexicon Pharmaceuticals, Inc. (LXRX)

Diabetes is a disorder of metabolism—the way the body uses digested food for growth and energy. Most of the food people eat is broken down into glucose, the form of sugar in the blood.

Glucose is vital to your health because it’s an important source of energy for the cells that make up your muscles and tissues. It’s also your brain’s main source of fuel.

The three main types of diabetes are: type 1 diabetes, type 2 diabetes and gestational diabetes.

Type 1 diabetes is a serious condition affecting more than one million people in the United States, both children and adults. Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas. A person who has type 1 diabetes must take insulin daily to live.

Symptoms of type 1 diabetes usually develop over a short period, although beta cell destruction can begin years earlier, and may include increased thirst and urination, constant hunger, weight loss, blurred vision, and extreme fatigue. If not diagnosed and treated with insulin, a person with type 1 diabetes can lapse into a life-threatening diabetic coma, also known as diabetic ketoacidosis.

LXRX reported positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control.

According to LXRX, the results from this study provide a clear demonstration of proof-of-concept of LX4211 as an oral, investigational new drug for type 1 diabetes complementing insulin therapy, and the magnitude of improved glycemic control by several measures, including HbA1c in only four weeks, and lower insulin requirements are highly encouraging and support the progression of LX4211 into late-stage development for type 1 diabetes

LXRX‘s LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action.

http://pennyomega.com/img/lxrx_chart.png

LXRX is focused on developing breakthrough treatments for human disease. LXRX has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by its research team.

More about Lexicon Pharmaceuticals, Inc. (LXRX) at www.lexpharma.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 420th community website in the U.S., associated with 1870 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://crwe-pr.com/wp-content/uploads/2013/12/CRWE_Network.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/bebe.jpg Bebe Stores, Inc. (BEBE)

BEBE was upgraded from Neutral to Buy with a price target of $7.50 by brokerage firm Janney Montgomery Scott

http://pennyomega.com/img/bebe_chart.png

BEBE is a global specialty retailer, which designs, develops and produces a distinctive line of contemporary women’s apparel and accessories under the bebe, BEBE SPORT, bbsp and 2b bebe brand names.

More about Bebe Stores, Inc. (BEBE) at www.bebe.com

**

http://pennyomega.com/img/adxs.jpg Advaxis, Inc. (ADXS)

ADXS said that the Japan Patent Office issued to the company two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to ADXS‘ proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

One of the patent applications allowed by the Japan Patent Office covers ADXS‘ immunotherapy treatments targeting factors that are essential for tumors or metastases to form new blood vessels (angiogenesis) or that are expressed by tumor blood vessels. The second patent applicationcovers the form of a recombinant attenuated auxotrophic Listeria having specific mutations conferring attenuation along with plasmid that complements the genomic mutation and also expresses a protein antigen fused to highly immunogenic Listeria peptides or other strongly immunogenic pathogen-associated peptide sequences.

It has already been established that attacking a tumor’s blood supply is an important strategy in preventing the tumor from growing and spreading and the addition of these two patents in Japan further allows ADXS to protect key elements of its proprietary cancer immunotherapies

http://pennyomega.com/img/adxsch.png

ADXS‘ immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.

More about Advaxis, Inc. (ADXS) at www.advaxis.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

Read our Disclaimer

 
Share/Bookmark
 



                

Crown Equity Holdings Inc., Added Medical Marijuana Site To Its CRWE-PR Network

http://pennyomega.com/img/crwe_logo.jpg

Las Vegas, NV, April 14, 2013 – (CRWE Press Release) – Crown Equity Holdings Inc. (OTCQB:CRWE) has announced that its CRWE-PR network is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

“Remember; in spite of medical marijuana use being legal in many states, as well as being recreational legal in Colorado and Washington; it is still deemed illegal on the Federal level.” stated Kenneth Bosket, President, “Therefore, the information, directory and news is primarily being provided for areas with legalized medical use of marijuana, while adding additional value to the CRWE-PR network.” Mr. Bosket added.

About Crown Equity Holdings Inc.

Together with its digital network of websites, Crown Equity Holdings Inc., offers advertising branding and marketing services as a worldwide online multi-media publisher. The company focuses on the distribution of information for the purpose of bringing together its targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors. For more information regarding Crown Equity Holdings Inc., please visit: http://www.crownequityholdings.com/.

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new business opportunities and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact
Kenneth Bosket, President
702 448-1543

SOURCE: Crown Equity Holdings Inc.

Read our Disclaimer

 
Share/Bookmark